ClinicalTrials.gg
RecruitingNCT05245136ALPSUpdated Jul 30, 2026

Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

An observational study in Characteristics Disease, Metastatic Cancer and Solid Tumor, sponsored by University Hospital Augsburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by University Hospital Augsburg · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 323 studies in Neoplasm Metastasis with a site in Germany — 52 open to participants now, 91 under way, 36 of them phase 3. Neoplasm Metastasis · Germany.

Planned enrollment
2nd of 25
3,000 · median 408
Started
2021
with 24 others
Observational
25 of 323
5 open now
Primary completion
2029-11
later than 79 of 90 live
Registered
263rd of 323
by date

Among the 323 studies in Neoplasm Metastasis with a site in Germany, this one is the 2nd largest by planned enrollment of the 25 observational ones that give a count, is one of 25 that started in 2021, is one of 25 observational ones, reaches primary completion later than 79 of the 90 other live ones, and was the 263rd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

52 of the 323 studies in Neoplasm Metastasis with a site in Germany are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 323 studies in Neoplasm Metastasis with a site in Germany, or all of them as a file.
02

Study summary

A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational research.

Read the detailed description

ALPS is a prospective observational trial to assess liquid biopsy as diagnostic tool in patients with various metastatic neoplasms. Liquid biopsy will be correlated not only with the tissue biopsy, but also to imaging modalities and classical tumor markers. In addition, the study aims to investigate clonal heterogeneity and evolution of different cancers during patient treatment courses. A third aspect of the study is to survey and assess patients' knowledge about biomarkers and personalized medicine in general and about liquid biopsy as a new diagnostic tool.

03

Conditions studied

  • Characteristics Disease
  • Metastatic Cancer
  • Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population consists of patients with diagnosis of metastatic cancer at the University Hospital Augsburg.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age ≥ 18 years
  • Histopathologically confirmed or locally advanced cancer
  • No curative treatment options, except for germ cell tumors
  • Written Agreement to be followed up at Augsburg University Medical Center
  • Signed written informed consent for the Biobank Augsburg (Biobank-A)
  • Willing to undergo treatment according to standard of care
  • Availability or anticipated availability of tumor tissue at time point of inclusion
  • Anticipated of at least 3 months at time point of trial inclusion

Exclusion criteria

Exclusion Criteria:

  • Psychological condition that would preclude
  • Additional tumor treatment between acquisition of tumor tissue and trial inclusion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Correlation of tumor mutations between tissue biopsy (TBx) and liquid biopsy (LBx) at diagnosis

    Correlation of tumor mutations between TBx and LBx at diagnosis with TBx as reference method based on PPA (positive percent agreement) and NPA (negative percent agreement)

    Time frame: through study completion, an average of 3 years

  2. Concordance between TBx and LBx at disease progression

    Concordance between TBx and LBx at disease progression with TBx as reference method based on PPA (positive percent agreement) and NPA (negative percent agreement)

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary outcomes

  1. Investigation of tumor heterogeneity as a prognostic marker

    Correlation of known and potential oncogenic drivers with imaging modalities based on morphological therapeutic response: ORR in classical entities and pools of tumor entities with ≥ 40 patient sample size

    Time frame: through study completion, an average of 3 years

  2. Correlation of known and potential oncogenic drivers in LBx with DCR

    Correlation of known and potential oncogenic drivers with imaging modalities based on morphological therapeutic response: DCR in classical entities and pools of tumor entities with ≥ 40 patient sample size

    Time frame: through study completion, an average of 3 years

  3. Correlation of known and potential oncogenic drivers in LBx with OS

    Correlation of presence of known and potential oncogenic drivers in LBx with OS per classical tumor entities and pools of tumor entities with ≥ 100 patient sample size

    Time frame: through study completion, an average of 3 years

  4. Role of a single numeric value (Shannon-Heterogeneity Index) at diagnosis as a surrogate marker for tumor heterogeneity

    to evaluate the role of a single numeric value (Shannon-Heterogeneity Index) at diagnosis as a surrogate marker for tumor heterogeneity

    Time frame: through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Nov 2029, 104 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 104 months is above that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Feb 17, 2022
StartActual
Mar 29, 2021
Primary completionEst.
Nov 2029
CompletionEst.
Mar 2030
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245136
Lead sponsor
University Hospital Augsburg
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Mar 29, 2021
Primary completion
Nov 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
Jul 30, 2026

Study contacts

Sommer Sebastian, MD
Contact
sebastian.sommer@uk-augsburg.de
+49-821400 ext. 161027
Rainer Claus, MD
Contact
rainer.claus@uk-augsburg.de
+49-821400 ext. 3715
Maximilian Schmutz, MD
principal investigator · UH Augsburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion